As per MRFR analysis, the US Genetic Engineering Market Size was estimated at 380.8 (USD Million) in 2023. The US Genetic Engineering Market Industry is expected to grow from 500(USD Million) in 2024 to 4,050 (USD Million) by 2035. The US Genetic Engineering Market CAGR (growth rate) is expected to be around 20.945% during the forecast period (2025 - 2035).
In the US Genetic Engineering Market, key market drivers are pushing the field forward as innovations continue to evolve. Federal policies supporting biotechnology, such as the Coordinated Framework for the Regulation of Biotechnology, provide a structured pathway for genetically engineered products, encouraging both research and commercialization. Enhanced funding from initiatives like the National Institutes of Health (NIH) and the United States Department of Agriculture (USDA) has also played a significant role in driving advancements in genetic engineering technologies. Opportunities abound in areas such as agriculture, where genetically modified organisms (GMOs) offer prospective solutions to food security issues and sustainability challenges.Additionally, there is a growing interest in gene therapies and precision medicine, providing a fertile ground for developing targeted treatments for various genetic disorders.
Trends in recent times reveal a notable shift towards public acceptance and ethical considerations surrounding genetic engineering applications. The US population shows increasing curiosity and support for biotechnology that promises safe food systems and health benefits. Moreover, advancements in CRISPR technology and gene editing are capturing significant attention, allowing for precise modifications in organisms, which could lead to enhanced crop yields and disease resistance.Regulatory bodies are gradually adapting to these changes, seeking to balance innovation with safety and ethical guidelines. The rise of plant-based and lab-grown food products is also influencing the market, pushing for integrated approaches that utilize genetic engineering within sustainable models. Continuous research and advocacy are shaping the landscape, leading to a more informed dialogue between scientists, policymakers, and the public. Thus, the US Genetic Engineering Market stands at the crossroads of rapid advancements and emerging societal implications.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The rising incidence of genetic disorders and diseases in the United States is expected to significantly drive growth in the US Genetic Engineering Market Industry. According to the Centers for Disease Control and Prevention (CDC), approximately 1 in 33 babies is born with a genetic disorder, indicating a growing patient population requiring innovative solutions such as genetic engineering. Furthermore, as healthcare technologies evolve, there is a strong demand for advanced therapeutic techniques including genomic medicine and gene therapy.Major organizations such as the National Institutes of Health (NIH) and the American Society of Human Genetics (ASHG) are actively supporting research and initiatives aimed at understanding and treating genetic conditions, further driving investment and interest in the genetic engineering sector. The potential for genetic engineering to offer targeted treatments and potentially curative therapies also enhances its appeal, prompting increased funding and collaboration across research institutions and biotechnology firms.
The US Genetic Engineering Market Industry is propelled by significant advancements in genetic engineering technologies such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). The growing availability and capability of gene-editing technologies are simplifying the modification of genetic material, making it more accessible for various applications. As reported by the National Science Foundation, funding for biotechnology research and development in the US has seen a substantial increase, which supports innovation in genetic engineering techniques.Institutions such as Stanford University and MIT are at the forefront of developing these technologies, thus influencing the market dynamics through advancements that reduce the time and costs associated with genetic engineering processes. This creates ample opportunities for companies to innovate and market products in the genetic engineering space.
Government policies and regulations play a pivotal role in shaping the US Genetic Engineering Market Industry. The United States government has shown a strong commitment to supporting biotechnological advancement through grants and legislative initiatives aimed at fostering innovative research. For instance, the Executive Order on Advancing Biotechnology and Biomanufacturing outlines significant federal investment aimed at ensuring the US maintains its leadership in biotechnology innovation.This proactive approach by federal agencies such as the Food and Drug Administration (FDA) and the Department of Agriculture (USDA) has led to streamlined regulatory pathways, encouraging companies to invest in genetic engineering solutions that could address pressing health issues and food security challenges faced by the nation.
The growing need for sustainable agricultural practices is driving demand for genetically modified crops in the US Genetic Engineering Market Industry. According to the United States Department of Agriculture (USDA), the adoption of genetically engineered crops has enabled farmers to increase yield while minimizing pesticide use and reducing environmental impact. With food security becoming an increasing concern amidst population growth, the use of genetically engineered crops presents solutions that enhance food production efficiency.Organizations like the American Farm Bureau Federation are advocating for the benefits of genetic engineering in agriculture by promoting policies that encourage the use of biotechnology in farming, thus enhancing adoption rates and driving market growth.
The US Genetic Engineering Market is exhibiting substantial growth driven by advancements in biotechnology and genetics, particularly in the Product segment. Within this segment, Biochemical and Genetic Markers are gaining traction due to their crucial applications in various industries including healthcare, agriculture, and research. The utilization of Biochemicals in genetic engineering allows for the development of innovative therapies and diagnostics, playing a pivotal role in precision medicine. As the focus on personalized healthcare continues to rise, Biochemicals are proving essential in creating targeted treatments that cater to individual genetic profiles. This trend is reflected in the increasing demand for biopharmaceuticals and the development of novel drugs, as they harness the power of genetic engineering to enhance efficacy and reduce side effects. Meanwhile, Genetic Markers are significant in facilitating advancements in genetic research and forensics, as they help identify specific traits or predispositions to diseases in various organisms.
Their application is substantial in crop improvement, allowing for the development of genetically modified organisms that can withstand environmental stresses and disease, boosting food security. Moreover, the evolving landscape of genomic data analysis emphasizes the need for accurate and reliable Genetic Markers, contributing to significant advancements in both medical diagnostics and agricultural biotechnology. This growing emphasis on genetic innovation aligns with nationwide initiatives aimed at enhancing health outcomes and agricultural efficiency, reinforcing the importance of these components in the overall US Genetic Engineering Market data.
The robust growth of this market segment is supported by ongoing Research and Development activities, which are likely to continue shaping the future of genetic engineering and its expansive market segmentation. The implications of these advancements stretch far beyond the laboratory, influencing both policy and public health markers, demonstrating the integral role that these particular elements of the Product segment play in the overarching US Genetic Engineering Market industry.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Devices segment of the US Genetic Engineering Market plays a crucial role in the advancement of biotechnological applications, as it encompasses essential tools such as PCR (Polymerase Chain Reaction), Gene Guns, and Gel Assemblies. PCR stands out for its ability to amplify DNA, making it indispensable in various fields including Research and Development, diagnostics, and forensic science, significantly driving the market growth. The Gene Gun, another notable technology, is pivotal in gene transfer processes, particularly in plant genetics, facilitating the creation of genetically modified organisms that address agricultural challenges.Gel Assemblies are vital for visualizing and analyzing DNA and RNA samples, serving as a foundational technique in molecular biology labs. With a robust supporting framework from regulatory bodies, coupled with increasing investments in Research and Development, the Devices segment is set to enhance the efficiency and accuracy of genetic engineering processes. The focus on these technologies reflects the industry's commitment to innovation and meets the rising demand for advanced genetic manipulation methods in the US market.
The Technique segment of the US Genetic Engineering Market showcases innovative methodologies driving advancements in the field, particularly focusing on Artificial Selection and Gene Splicing. Artificial Selection has remained a fundamental practice, allowing the manipulation of traits in organisms to enhance desirable characteristics. This technique plays a critical role in agriculture, contributing significantly to crop yield improvement and disease resistance, aligning with the increasing demand for sustainable food production in the US. Gene Splicing, on the other hand, offers the ability to directly alter an organism's genetic material, paving the way for groundbreaking treatments in medicine, including gene therapies for genetic disorders.
As research in Genetic Engineering progresses, these techniques are becoming increasingly significant, responding to the challenges of food security and health care. The current trends showcase a surge in investments targeted towards these methodologies, driven by the potential for large-scale applications and effective solutions to critical societal challenges. With robust support from government initiatives, these segments are poised to dominate the US Genetic Engineering Market, reflecting a strong alignment with the shifting priorities in health and agricultural sectors.
The Application segment of the US Genetic Engineering Market is a critical area driving innovation and development across various sectors. The Agriculture sector leverages genetic engineering to enhance crop resilience, yield, and nutritional value, thereby addressing food security challenges and adapting to climate change. This segment plays a significant role in developing genetically modified organisms (GMOs) that are crucial for modern agricultural practices. In the Medical Industry, genetic engineering facilitates advancements in gene therapy, personalized medicine, and biopharmaceuticals, significantly improving patient outcomes and treatment efficacy.
The US Genetic Engineering Market segmentation highlights the importance of these applications as they pave the way for revolutionary breakthroughs in healthcare and sustainable farming practices. Key growth drivers for this market include increasing demand for food due to population growth, stringent regulations promoting advanced biotechnologies, and rising investment in research and development initiatives. However, challenges such as regulatory hurdles and public perception of genetically engineered products remain prevalent. Nonetheless, the continuous evolution of genetic engineering tools presents ample opportunities for further innovation, making these applications vital for future advancements in both agriculture and medicine.
The US Genetic Engineering Market is characterized by a dynamic landscape where technological advancements and innovation spur competition among a diverse range of companies. As genetic engineering continues to evolve, organizations within this sector strive to maintain or enhance their market position through research and development, strategic partnerships, and product diversification. The competitive insights reveal a market driven by a mix of established players and emerging startups, all vying to leverage genetic technologies for applications that range from agriculture to healthcare. The rapid pace of advancements in gene editing technologies, including CRISPR and genome sequencing, has intensified competition, compelling companies to invest heavily in new methodologies and solutions that can address the ever-increasing demand for personalized medicine and agricultural efficiency.
Illumina stands as a prominent player in the US Genetic Engineering Market, recognized for its innovative sequencing technologies and contributions to genomics research. The company has established a solid market presence through its advanced sequencing platforms, which have become integral to both clinical applications and scientific research. Illumina's strengths lie in its ability to continuously evolve its product offerings, ensuring they remain at the forefront of genomic discovery and precision medicine. This commitment to innovation is supported by significant investments in research and collaboration with academic institutions and healthcare organizations, allowing Illumina to maintain leadership in developing tools that facilitate comprehensive genomic analysis.
Genentech, another key entity in the US Genetic Engineering Market, is known for its pioneering role in biotechnology and the therapeutic applications of genetic engineering. The company boasts a robust portfolio of biologic therapies that focuses on areas such as cancer, immunology, and neuroscience, driven by a strong commitment to research and development. Genentech's market presence is strengthened by its strategic mergers and acquisitions, which have augmented its capabilities in genetic engineering and expanded its product line. The company's strengths include its rich pipeline of innovative treatments, a solid reputation for quality among its peers, and an ongoing dedication to delivering breakthrough therapies that enhance patient outcomes. By integrating advanced genetic technologies into its research and production processes, Genentech continues to solidify its position as a leader in the competitive landscape of genetic engineering within the US.
The US Genetic Engineering Market has seen significant activity recently, especially with companies such as Illumina, Genentech, Zymeworks, and Editas Medicine making strides in Research and Development. In October 2023, Editas Medicine announced a collaboration with a major pharmaceutical company to enhance its gene-editing technologies. Additionally, Genentech reported advancements in its portfolio targeting genetic therapies for rare diseases. The growing investment in CRISPR technology has been underscored by CRISPR Therapeutics engaging in further development initiatives, projected to positively impact the market valuation, which has been estimated to reach over $70 billion by 2025. In August 2022, Thermo Fisher Scientific acquired the assets of a leading gene synthesis firm, boosting its capabilities in genetic analysis. Monsanto and Corteva are also expanding their gene editing techniques in agricultural biotechnology, reflecting a growing trend to enhance crop resistance. The US Genetic Engineering Market is marked by innovation and collaboration among major players as they seek to address biotechnology challenges while maintaining regulatory compliance from bodies like the Food and Drug Administration.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 380.8(USD Million) |
| MARKET SIZE 2024 | 500.0(USD Million) |
| MARKET SIZE 2035 | 4050.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 20.945% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Illumina, Genentech, Zymeworks, DowDuPont, Editas Medicine, Genomatica, AMGEN, CRISPR Therapeutics, Thermo Fisher Scientific, Regeneron Pharmaceuticals, Agilent Technologies, Ginkgo Bioworks, Monsanto, Novozymes, Corteva |
| SEGMENTS COVERED | Product, Devices, Technique, Application |
| KEY MARKET OPPORTUNITIES | Agricultural biotechnology advancements, Gene therapy innovations, CRISPR technology applications, Personalized medicine development, Sustainable bioengineering solutions |
| KEY MARKET DYNAMICS | Regulatory frameworks, Research and development funding, Public perception and acceptance, Agricultural applications growth, Biotechnology innovation and collaboration |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Genetic Engineering Market is expected to be valued at approximately 4050.0 USD Million by 2035.
In 2024, the market size of the US Genetic Engineering Market is estimated to be around 500.0 USD Million.
The market is projected to grow at a CAGR of 20.945% from 2025 to 2035.
Major players in the market include Illumina, Genentech, Zymeworks, and Thermo Fisher Scientific among others.
The market for Biochemical products is valued at 150.0 USD Million in 2024.
The market size for Genetic Markers is expected to reach 2550.0 USD Million by 2035.
Key applications include drug development, agricultural biotechnology, and genetic testing, among others.
The current global scenario presents both challenges and opportunities, potentially influencing market dynamics positively.
The market value for the Biochemical products segment is projected to be around 1500.0 USD Million by 2035.
Emerging trends include advancements in CRISPR technology and increased investment in gene therapy research.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
